NMIN
VIDEOS
Thanks to all the presenters, sponsors and participants in Vancouver Nanomedicine Day 2021 for making it another memorable and informative experience.
Recordings of most sessions from the event are available below.
Welcome & Introduction to Nanomedicines
Urs Häfeli
University of British Columbia
Organizer, Vancouver Nanomedicine Day 2021
INVITED TALK: Nanomedicines for oral delivery of peptides ‐ what have we learned?
David Brayden
University College Dublin,Ireland
In vivo and phantom imaging of cyclotron produced 133La as a theranostic radionuclide for 225Ac and 135La
Bryce Nelson
University of Alberta
Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV‐infected cells
Ekaterina Dadachova
University of Saskatchewan
Customizable multifunctional metal nanotexaphyrin as a radiotheranostics agent for cancer imaging and therapy
Miffy Cheng
University of Toronto
Smart nanomaterials: a multi‐pronged strategy towards targeting bacteria
Ruby Sullan
University of Toronto Scarborough
Sprayable nanoparticle network hydrogels for promoting intranasal drug delivery to the brain
Todd Hoare
McMaster University
Nano‐delivery of novel inhibitors of DNA repair for targeted chemo‐ and radio‐sensitization of solid tumors
Afsaneh Lavasanifar
University of Alberta
INVITED TALK: Magnetized nanocarriers targeting brain delivery after stroke
Anna Rosell
Vall d’Hebron Institute of Research, Barcelona, Spain
KEYNOTE: Nucleoside‐modified LNP mRNA therapeutics
Drew Weissman
University of Pennsylvania, PA, USA
MicroRNA‐145 delivery by targeted peptide micelles for atherosclerosis therapy
Deborah Chin
University of Southern California, CA, USA
Development and optimization of LNP‐based gene therapy approaches in the brain
Blair Leavitt
Centre for Molecular Medicine and Therapeutics, UBC
NMIN
About
This world-class symposium, the seventh event of its kind, gathered renowned Canadian and international experts from across the nanomedicines field to:
- highlight the discoveries and innovations in nanomedicines that are contributing to global progress in acute, chronic and orphan disease treatment and management;
- present up-to-date diagnostic and therapeutic nanomedicine approaches to addressing the challenges of COVID-19; and
- facilitate discussion among nanomedicine researchers and innovators and UBC and NMIN clinician-scientists, basic researchers, trainees, and research partners.
Since 2014, Vancouver Nanomedicine Day has advanced nanomedicine research, knowledge mobilization and commercialization in Canada by sharing high-impact findings and facilitating interaction—among researchers, postdoctoral fellows, graduate students, and life science and startup biotechnology companies—to catalyze research collaboration.
Organizer:
Dr. Urs Häfeli, PhD, Professor of Pharmaceutical Sciences at the University of British Colombia
Nanomedicine is an interdisciplinary research area within nanotechnology that aims to develop medical technologies at the nanoscale, ranging from drug delivery carriers and imaging agents to nanomaterials and nanoelectronic biosensors.
A cluster of researchers at the University of British Columbia (UBC) has organized this event since 2014.
NMIN
PROGRAM
Virtual Vancouver Nanomedicine Day 2021 featured:
- A keynote address by the physician-scientist best known for his contributions to RNA biology, enabling the development of effective mRNA vaccines: Dr. Drew Weissman (University of Pennsylvania)
- Invited talks by internationally renowned experts, including Dr. David Brayden (University College Dublin, Ireland), and Dr. Anna Rosell (Vall d’Hebron Institute of Research, Barcelona, Spain)
- Presentations by other leading experts, including: Frank Wuest (University of Alberta), Ekaterina Dadachova (University of Saskatchewan), Miffy Cheng (University of Toronto), Ruby Sullan (University of Toronto Scarborough), Todd Hoare (McMaster University), Afsaneh Lavasanifar (University of Alberta), Suzie Pun (University of Washington), Deborah Chin (University of Southern California) and Blair Leavitt (University of British Columbia)
NOTE that all times in the program are in Pacific Daylight Time (PDT).
Featured speakers
University of Alberta
University of British Columbia
Nucleoside-modified LNP mRNA therapeutics
Drew Weissman, University of Pennsylvania (USA)
Nanomedicines for oral delivery of peptides – what have we learned?
David Brayden, University College Dublin (Ireland)
Magnetized nanocarriers targeting brain delivery after stroke
Anna Rosell, Vall d’Hebron Institute of Research (Spain)
NMIN
REGISTRATION
Registration to Virtual Vancouver Nanomedicine Day 2021 is free.
However, your advance registration is required for planning purposes.
We look forward to including you on September 16, 2021!
There is no registration fee for this event, but registration is required.
Upon registering, you will be emailed a link to join the event.
NO PARTICIPATION LINK?
Did you register for this event without ever receiving a participation link by email?
Please register by September 4, 2019
NMIN
sponsors
tHANKS TO OUR SPONSORS
GOLD
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
NanoVation Therapeutics (NVT) is an early-stage gene therapy company focused on developing personalised therapeutics to treat age-related conditions using lipid nanoparticle and nucleic acid-based technologies. NVT develops next-generation platform technologies to enable efficient extrahepatic gene therapy and is available for partnering opportunities.
The NanoMedicines Innovation Network (NMIN) is a federally-funded national research network that brings investigators from universities across Canada together with industry and public sector partners to expand and improve Canada’s position as world leader in nanomedicines R&D.
SILVER
Uniquely operated in British Columbia as an independent CRO, BRI focuses on pre-clinical and clinical programs supporting biotech and pharmaceutical companies. BRI has capabilities in LC/MS/MS and multiplex ELISA bioanalytical, in-vivo and in-vitro drug metabolism, pharmacokinetics and human tumor xenograft mouse models.
Malvern Panalytical provides analytical systems and solutions which enable complex biophysical profiles to be characterized. Our approach includes a range of orthogonal and complementary analytical techniques along with consultation and applications expertise.
PNI is a global leader in technology and solutions for developing RNA, DNA, CRISPR, small molecule drugs, COVID vaccines and therapeutics rapidly taking ideas to patients.
STEMCELL Technologies Inc. supports global life sciences research with more than 2,500 specialized tools and services. They provide high quality cell culture media, cell separation technologies, instruments, accessory products and scientific services that are used by scientists conducting stem cell biology, immunology, cancer, regenerative medicine, and cellular therapy research.
BRONZE
Acuitas is a private company based in Vancouver, British Columbia that is partnered with multiple pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the clinic and to the marketplace. We work with partners to develop new therapies to address unmet clinical needs based on our internationally recognized capabilities in delivery technology.
Evonik, a global development and solutions partner to the pharma industry for over 60 years, provides drug delivery technologies, excipients, API manufacturing, intermediates, amino acid derivatives, and advanced food ingredients. As a leading CDMO, services include formulation & process development, GMP manufacturing & aseptic filling of drug products.
PHARMA INVENTOR INC. is a Canadian Chemistry R&D services company based in Vancouver, BC. We are very proud to service the Life Science BC community since 2013 and be recognized by them for our expertise in Medicinal Chemistry, Custom Organic Synthesis and Process Research & Development. Our mission is to provide inventive, reliable, cost-effective & high-quality chemistry solutions to our clients’ discovery R&D programs.
Founded in 1946, the Faculty of Pharmaceutical Sciences at UBC enjoys an international reputation in pharmacy education, innovation in pharmacy practice, and research in the pharmaceutical sciences.
adMare BioInnovations is Canada’s Global Life Sciences Venture, building the Canadian life sciences industry from sea to sea. They partner with leading academic researchers and biotech companies to advance commercially promising therapeutic innovations to create new companies of scale; and offer specialized scientific and commercial expertise, infrastructure and capital to help existing companies scale up.
Genome BC is a non-profit research organization that leads genomics innovation on Canada’s West Coast and facilitates the adoption of genomics into society.